FDA Okays First Biosimilar for Multiple Sclerosis FDA Okays First Biosimilar for Multiple Sclerosis

Sandoz ' s natalizumab-sztn injection (Tyruko) is on par with Biogen ' s Tysabri (natalizumab) for treatment of relapsing forms of MS, the FDA said in approving the first biosimilar to treat MS.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news